In our study, administration of DR30318 resulted in a sustained elevation of CRP levels, potentially indicating an on-target off-tumor toxicity in the stomach, as evidenced by observed gastric-related adverse effects such as anorexia, nausea and mucosal damage (data not shown). Here, CRP is linked to neoplasm.